Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Emory University Bristol-Myers Squibb |
---|---|
Information provided by: | Emory University |
ClinicalTrials.gov Identifier: | NCT00209027 |
The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.
Condition | Intervention |
---|---|
Schizophrenia |
Drug: Aripiprazole (drug) |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Aripiprazole Effects on Reward Processing in Deficit Syndrome Schizophrenia |
Estimated Enrollment: | 30 |
Study Start Date: | April 2005 |
Estimated Study Completion Date: | December 2008 |
Ages Eligible for Study: | 20 Years to 50 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Subjects with Schizophrenia:
Inclusion Criteria:
Exclusion Criteria:
Control Subjects:
Inclusion Criteria:
Exclusion Criteria:
Contact: Bill Boshoven, BS | (404) 321-6111 ext 6982 | bill.boshoven@emory.edu |
United States, Georgia | |
Atlanta VA Medical Center | Recruiting |
Decatur, Georgia, United States, 30033 | |
Contact: Bill Boshoven, BS 404-321-6111 ext 6982 bill.boshoven@emory.edu | |
Principal Investigator: Erica Duncan, MD |
Principal Investigator: | Erica Duncan, MD | Emory University/Atlanta VA Medical Center |
Study ID Numbers: | 570-024 |
Study First Received: | September 13, 2005 |
Last Updated: | November 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00209027 History of Changes |
Health Authority: | United States: Food and Drug Administration |
schizophrenia reward fMRI Aripiprazole |
Schizophrenia Tranquilizing Agents Mental Disorders Psychotropic Drugs Central Nervous System Depressants |
Psychotic Disorders Aripiprazole Antipsychotic Agents Schizophrenia and Disorders with Psychotic Features |
Schizophrenia Tranquilizing Agents Mental Disorders Therapeutic Uses Physiological Effects of Drugs Psychotropic Drugs |
Central Nervous System Depressants Aripiprazole Antipsychotic Agents Central Nervous System Agents Pharmacologic Actions Schizophrenia and Disorders with Psychotic Features |